Literature DB >> 8648105

An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.

G Papoff1, I Cascino, A Eramo, G Starace, D H Lynch, G Ruberti.   

Abstract

Fas/Apo-1 molecule, also designated as CD95, is a member of the TNF receptor family. Fas cross-linking by its natural ligand or by agonistic mAbs results in rapid induction of apoptosis in susceptible cells. in addition to the Fas full-length mRNA, human activated PBMC and tumor cell lines express several mRNA Fas variants that derive from alternative splicing of the primary transcript. All five variants identified, two of which are newly described here, code for soluble proteins that, with the exception of FasTMDel, are truncated in the extracytoplasmic region and possess short C-terminal amino acid sequences corresponding to a different reading frame. We have identified Abs that recognize all splicing variants and established a sandwich ELISA by which the soluble Fas molecules could be detected in culture supernatants of transfected cell lines and in PBMC following T cell activation. Next, we have studied in detail the functional role of these variants by apoptosis inhibition studies. We found that all soluble proteins block the apoptosis induced by either an agonistic Ab or, more importantly, by the natural Fas ligand in Fas-positive sensitive cell lines. interestingly, this functional property can be assigned to the first 49 amino acids of the mature protein that is the only region shared by the five soluble Fas molecules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648105

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis.

Authors:  S Whitman; X Wang; R Shalaby; E Shtivelman
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease.

Authors:  Der-Yuan Chen; Joung-Liang Lan; Fang-Ju Lin; Tsu-Yi Hsieh
Journal:  Clin Rheumatol       Date:  2006-09-14       Impact factor: 2.980

Review 3.  Apoptosis in B-chronic lymphocytic leukaemia.

Authors:  L M Osorio; M Aguilar-Santelises
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

4.  Soluble Fas mRNA is dominantly expressed in cases with silicosis.

Authors:  T Otsuki; H Sakaguchi; A Tomokuni; T Aikoh; T Matsuki; Y Kawakami; M Kusaka; H Ueki; S Kita; A Ueki
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

5.  Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.

Authors:  Jordi Codony-Servat; Xabier Garcia-Albeniz; Carles Pericay; Vicente Alonso; Pilar Escudero; Carlos Fernández-Martos; Rosa Gallego; Anna Martínez-Cardús; Eva Martinez-Balibrea; Joan Maurel
Journal:  Med Oncol       Date:  2013-01-22       Impact factor: 3.064

6.  FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

Authors:  L Sehgal; R Mathur; F K Braun; J F Wise; Z Berkova; S Neelapu; L W Kwak; F Samaniego
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

7.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

9.  Serum markers of apoptosis decrease with age and cancer stage.

Authors:  Nilay Kavathia; Alka Jain; Jeremy Walston; Brock A Beamer; Neal S Fedarko
Journal:  Aging (Albany NY)       Date:  2009-07-14       Impact factor: 5.682

10.  Serum IP-10 is useful for identifying renal and overall disease activity in pediatric systemic lupus erythematosus.

Authors:  Chen-Xing Zhang; Li Cai; Kang Shao; Jing Wu; Wei Zhou; Lan-Fang Cao; Tong-Xin Chen
Journal:  Pediatr Nephrol       Date:  2017-12-20       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.